Absci vs Atomwise
Side-by-side comparison
| Absci | Atomwise | |
|---|---|---|
| Product | Absci Drug Creation | AtomNet |
| Category | Drug Discovery AI | Drug Discovery AI |
| What it does | Unlocking new drug candidates faster by integrating AI with proprietary wet-lab data. | Deep-learning virtual screening to find novel small-molecule hits faster |
| Pricing model | Partnership / Per Project | Partnership / Per Project |
| Free trial | No | No |
| Target company size | Enterprise, Mid-Market | Enterprise, Mid-Market |
| Deployment | Cloud/SaaS | Cloud/SaaS |
| Integrations | Laboratory Automation, Protein Expression Systems | Molecular Databases, Laboratory Systems |
| API available | Yes | — |
| Certifications | SOC 2 Type II, ISO 27001 | — |
About Absci Drug Creation
Absci Drug Creation is an AI-powered drug discovery platform that integrates generative AI with high-throughput wet-lab data to design, predict, and optimize novel therapeutic proteins. It is used by biopharmaceutical companies and researchers to accelerate drug discovery, de-risk development, and bring better therapeutics to market faster. Its key differentiation lies in its ability to generate a
Use cases: Discovery of novel antibody therapeutics with enhanced binding and developability., Optimization of existing protein drugs for improved stability, potency, or reduced immunogenicity., Identification and validation of novel therapeutic targets for various disease areas., Accelerated lead candidate selection by predicting key properties early in the discovery funnel., De-risking drug development by assessing developability and manufacturability of candidates.
About AtomNet
AtomNet is Atomwise’s (now Numerion Labs) structure-based AI platform that predicts protein–small-molecule binding to accelerate early drug discovery. It is used by pharma/biotech R&D teams and academic labs to run virtual high-throughput screening (vHTS) across extremely large, synthesizable chemical libraries and prioritize compounds for synthesis and experimental testing. The business value is
Use cases: Virtual high-throughput screening to identify initial hits for a protein target, Finding novel scaffolds for targets with limited or no known ligands (hard-to-drug targets), Prioritizing compounds for synthesis-on-demand procurement and experimental validation, Supporting partner programs from hit identification through lead optimization and candidate selection, Running multi-target discovery programs within strategic pharma collaborations